Exagen Inc. (XGN)
NASDAQ: XGN · Real-Time Price · USD
9.20
+0.21 (2.34%)
At close: Aug 8, 2025, 4:00 PM
9.31
+0.11 (1.20%)
After-hours: Aug 8, 2025, 7:54 PM EDT
Chuy's Holdings Revenue
Exagen had revenue of $17.20M in the quarter ending June 30, 2025, with 14.19% growth. This brings the company's revenue in the last twelve months to $58.86M, up 3.89% year-over-year. In the year 2024, Exagen had annual revenue of $55.64M with 5.89% growth.
Revenue (ttm)
$58.86M
Revenue Growth
+3.89%
P/S Ratio
2.98
Revenue / Employee
$273,777
Employees
215
Market Cap
202.43M
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 55.64M | 3.09M | 5.89% |
Dec 31, 2023 | 52.55M | 6.99M | 15.33% |
Dec 31, 2022 | 45.56M | -2.74M | -5.66% |
Dec 31, 2021 | 48.30M | 6.32M | 15.07% |
Dec 31, 2020 | 41.98M | 1.59M | 3.93% |
Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2014 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
UnitedHealth Group | 422.82B |
Johnson & Johnson | 90.63B |
Merck & Co. | 63.62B |
AbbVie | 58.33B |
AstraZeneca | 56.50B |
Novartis AG | 55.19B |
Eli Lilly and Company | 53.26B |
Novo Nordisk | 49.11B |
XGN News
- 2 days ago - Exagen Inc. to Participate in Third Quarter Investor Conferences - GlobeNewsWire
- 10 days ago - Exagen Inc. (XGN) Q2 2025 Earnings Call Transcript - Seeking Alpha
- 11 days ago - Exagen Inc. Reports Strong Q2 2025 Results - GlobeNewsWire
- 22 days ago - Exagen Inc. Appoints Chas McKhann to Board of Directors - GlobeNewsWire
- 24 days ago - Exagen Inc. to Announce Second Quarter 2025 Financial Results on July 29, 2025 - GlobeNewsWire
- 6 weeks ago - Michael Mahler, PhD Joins Exagen as Chief Scientific Officer to Enhance Leadership in Autoimmune Diagnostics - GlobeNewsWire
- 3 months ago - Exagen Inc. Announces Closing of $20.2 Million Public Offering Including Full Exercise of Underwriter's Option to Purchase Additional Shares - GlobeNewsWire
- 3 months ago - Exagen Inc. Prices Public Offering of Common Stock - GlobeNewsWire